Publication date: Jul 03, 2019
This post was originally published on this site NervGen wants to advance the development of NVG-291, its lead investigational therapy for spinal cord damage, as a potential remyelination treatment for multiple sclerosis (MS), the company announced. Following preclinical data showing that NVG-291 promotes myelin repair and regeneration of damaged nerves in animal models of spinal cord injury and MS, the compound has attracted pharma’s attention as a potential therapy for these and other neurodegenerative conditions. Blocking PTPσ with NVG-291 has been shown to promote regeneration of damaged nerves, improving nerve function in animal models for various medical conditions, according to NervGen. -As we advance our lead drug candidate, NVG-291, towards a Phase 1 clinical trial in Q1 2020 for spinal cord injury, we are leveraging the potential for our drug to also promote nerve remyelination as a therapy for MS,” Bill Radvak, NervGen’s executive chairman, said in a press release. The post NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS appeared first on Multiple Sclerosis News Today.
|pathway||BSID||Spinal Cord Injury|
- Emerald Health Pharmaceuticals Demonstrates Repair of Nerve Damage Related to Multiple Sclerosis
- Development and optimisation of an animal model for the study of ganglion cells in degenerative diseases of the retina and optic nerve.
- Therapeutic Potential of Kappa Opioid Agonists.
- Pericytes in Multiple Sclerosis.
- Tracking the evolution of CNS remyelinating lesion in mice with neutral red dye.
- The role of fatty acid binding protein 7 in spinal cord astrocytes in a mouse model of experimental autoimmune encephalomyelitis.